MedPath

Watchdog to Review FDA's Approval Process for Biogen's Alzheimer's Drug

The Department of Health and Human Services' Office of Inspector General will review the FDA's accelerated approval process for Biogen's Alzheimer's drug, Aduhelm, following controversy over regulatory standards and the drug's efficacy.

The Department of Health and Human Services' Office of Inspector General (HHS OIG) has announced it will review the Food and Drug Administration's (FDA) process for approving Biogen's Alzheimer's drug, Aduhelm. This decision comes after the FDA's approval of Aduhelm sparked unprecedented controversy over regulatory standards and the drug's efficacy.
The HHS OIG will specifically examine the accelerated approval pathway used by the FDA, which allows for quicker approvals of drugs treating serious conditions with unmet medical needs. This pathway was utilized for Aduhelm's approval two months ago, despite initial doubts about the drug's effectiveness based on two clinical trials. Biogen reanalyzed the data, finding a modest slowing of cognitive decline in one trial's high-dose participants, while the other trial showed no benefit.
Acting FDA Commissioner Janet Woodcock requested the OIG review, following concerns over the FDA's proactive role in assisting Biogen through the approval process, including drafting a roadmap for approval. This has raised questions about the FDA's independence and objectivity, especially after an FDA advisory panel nearly unanimously recommended against the drug's approval.
The review will also look into the FDA's interactions with external parties and the decision-making process for the accelerated approval pathway, without assessing the scientific appropriateness of the drugs reviewed. The HHS OIG aims to ensure the integrity of the FDA's drug approval process and address stakeholders' concerns regarding Aduhelm's approval.
Aduhelm's approval has significant financial and health implications, with a wholesale list price of $56,000, far exceeding the cost-effective threshold. The FDA initially issued a broad label for the drug but later narrowed it to patients with mild cognitive impairment or mild Alzheimer's. The ongoing debate over Aduhelm's effectiveness has led Medicare to consider national coverage decisions, leaving many patients and insurers in uncertainty.
The FDA has defended its approval of Aduhelm, stating it fits within the accelerated approval pathway and reflects current scientific knowledge. However, the HHS OIG's review, expected to be completed by 2023, seeks to provide clarity and ensure the integrity of the FDA's approval process.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Inspector General Report Flags FDA's Accelerated Approvals of Aduhelm, Exondys, and Makena

An Inspector General report has raised concerns about the FDA's accelerated approval process for certain drugs, citing deviations from appropriate pathways.
The report specifically highlights Biogen's Aduhelm, Sarepta's Exondys, and Covis Pharma's Makena as examples where the FDA's judgment is questioned.

FDA's Accelerated Approval Pathway Faces Ethical Scrutiny and Calls for Reform

Scholars are debating the ethical implications and potential improvements to the FDA's accelerated approval pathway for drugs targeting serious conditions.
Concerns persist regarding the use of surrogate endpoints and the need for rigorous post-approval trials to confirm clinical benefits.

Alzheimer's Drug Trials Under Scrutiny for Genetic Risk Disclosure

Clinical trials for Alzheimer's drugs lecanemab (Leqembi) and donanemab-azbt (Kisunla) are under investigation for withholding genetic risk information from participants.
Participants were reportedly not informed about their genetic predispositions to brain injuries, despite signing consent forms acknowledging the risks.

Navigating Drug Approval: A Look at Regulatory Pathways for Huntington's Disease Therapies

Drug development involves rigorous clinical trials (Phases 1-3) to ensure safety and efficacy, with regulatory agencies like the FDA and EMA overseeing the process.
The FDA operates as a self-contained entity in the US, while the EMA involves multiple layers representing EU member states, influencing trial locations and approval timelines.

FDA Advisory Committee to Review Rare Disease Treatment Amid Efficacy Concerns

An FDA advisory committee will convene to evaluate a rare disease drug, a decision influenced by strong advocacy from patient communities.
The FDA has expressed concerns regarding the treatment's efficacy, highlighting the challenges of conducting trials for rare diseases with limited patient populations.

Donanemab Approval Under Scrutiny: Concerns Raised Over Safety, Efficacy, and Conflicts of Interest

An investigation raises concerns about the safety and efficacy of donanemab, a newly approved Alzheimer's drug, citing patient deaths and adverse events during trials.
Financial ties between FDA advisory committee members and the drug's manufacturer, Eli Lilly, and other related companies are under scrutiny for potential conflicts of interest.

FDA Issues Complete Response Letter for Dasiglucagon in Congenital Hyperinsulinism Due to Manufacturing Deficiencies

The FDA issued a Complete Response Letter (CRL) for Zealand Pharma's dasiglucagon for congenital hyperinsulinism (CHI) for up to three weeks of dosing.
The CRL is based on deficiencies identified at a third-party manufacturing facility and is not related to dasiglucagon's clinical data or safety.

Aducanumab Approval and Medicare Coverage: Implications for Alzheimer's Treatment

The FDA's approval of aducanumab, an antiamyloid antibody for early Alzheimer's, sparked controversy due to unclear clinical benefits and high cost.
CMS restricted Medicare coverage to patients in clinical trials, citing limited evidence and significant adverse effects, creating access barriers.

3 Experts Resign from FDA Panel Over Alzheimer's Drug Approval

Three experts have resigned from an FDA advisory committee following the controversial approval of Aduhelm, an Alzheimer's drug, against the panel's recommendations. The resignations highlight concerns over the drug's efficacy, approval process, and potential impact on future drug evaluations.

Biogen's Alzheimer's Drug in Spotlight Following Sarepta's Vyondys 53 Approval

The unexpected FDA approval of Sarepta Therapeutics' Vyondys 53 for Duchenne muscular dystrophy has sparked discussions about the potential flexibility the FDA might show towards Biogen's Alzheimer's drug, aducanumab. This comes amidst skepticism over the efficacy and safety of both drugs, with Biogen's application based on a controversial Phase 3 study.

Reference News

[1]
Watchdog will review FDA approval of Biogen's Alzheimer's drug
statnews.com · Aug 4, 2021

The HHS OIG will review the FDA's accelerated approval process for Biogen's Alzheimer's drug, Aduhelm, following controv...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy